Markets
Charles Liang, CEO of Super Micro
Charles Liang, CEO of Super Micro (Walid Berrazeg/Getty Images)

Super Micro sinks as Wall Street hates its trade-off of profitability for sales

Companies tied to the AI boom generally get rewarded for aggressively expanding capacity. That’s not the story this time.

Luke Kawa

Throughout the AI boom, investing aggressively in your near-term capabilities for the promise of bigger profits down the road has generally been applauded by investors.

Not so for Super Micro Computer, at least this quarter.

Shares of the server company are getting whacked this morning after its fiscal Q1 earnings report, where management delivered a much better Q2 sales outlook than analysts had anticipated, but with weaker-than-expected guidance for earnings per share. Profitability is taking a hit as the company offers preferential pricing to bigger customers and then looks to bolster its capacity to meet those huge orders, with hopes of many more to come.

“The company is placing greater investment for a strategic mega-scale AI win and expects margin to improve as it leverages investments,” Bloomberg Intelligence senior industry analyst Woo Jin Ho wrote. “This is no guarantee, as Super Micro didn’t provide a full-year margin outlook.”

When you’re selling umbrellas during a rain storm, you’re not only supposed to be able to sell more of them, but it’s also presumed that you’re able to display some decent pricing power that supports profitability.

Dell and Super Micro are both server companies looking to hitch their wagons to the explosive growth of AI. Their margin outlooks are heading in different directions.

“Supermicro received its largest design award in the company’s history, which is leading to better than expected revenue in F2Q26 and FY26,” Needham analyst N. Quinn Bolton wrote. “However, this program is expected to compress gross margin in the near term due to higher costs associated with the initial ramp along with lower margins this design award carries.”

Bolton cut his price target on the stock to $51 from $60. JPMorgan also reduced its price target to $40 (from $43), while Rosenblatt lowered its view of where shares are going to $55 from $60.

Not only this big contract, but also new production facilities that are being brought online to meet increased demand are expected to weigh on margins in the near term. To continue the analogy, to be able to sell umbrellas in a persistent downpour, you also need to be able to produce a lot of what people want to provide shelter from the storm.

During the conference call, executives were inundated with questions about the margin outlook.

“We’re going into a quarter where we are ramping one of the largest clusters in the world,” said CFO David Weigand. “We are ramping a new product line at mega scale. And so therefore, we were being a little conservative on the margin because we will have a higher cost as we ramp production and shipment.”

CEO Charles Liang said that a double-digit gross margin is still in Super Micro’s plans; it’s just going to “take a little bit longer.”

More Markets

See all Markets
markets

Lilly says its next-gen GLP-1 shot drove 28.3% weight loss, reduced comorbidities

Eli Lilly has risen around 4% in premarket trading after reporting impressive trial results for its next-generation weight-loss drug over the weekend.

According to the results unveiled on Saturday, Lilly’s experimental weight-loss shot, retatrutide, helped patients lose 28.3% of their body weight at 80 weeks. That’s more than tirzepatide, Lilly’s weight-loss shot currently considered the most effective in the market, which helped people lose 26% of their weight over 88 weeks.

Retatrutide is a triple agonist, meaning it mimics three different hormones that promote weight loss, compared to one by Novo Nordisk’s semaglutide and two by tirzepatide. Lilly says it helps preserve more muscle mass than other weight-loss shots and also helped improve knee osteoarthritis pain and obstructive sleep apnea.

Lilly has said it would submit the drug for approval this year with the goal of getting it out to market in 2027. The jab could be the next big money-maker for Lilly, which currently sells the most lucrative drug in the world but has had an underwhelming rollout of its oral weight-loss pill, which came to market earlier this year.

Retatrutide is already quite popular among those who experiment with peptides, or unapproved injectable drugs often sold online “for research purposes only.” For gym bros trying to attain a certain physique, a drug that has shown it can melt fat while preserving muscle is enticing.

But in a market full of knock-off drugs, will retatrutide enthusiasts pay full price for the drug when it officially goes to market?

markets

Marvell and Flex rise on S&P 500 inclusion announcement

Chipmaker Marvell Technology and electronics manufacturer Flex are jumping 7% and 3%, respectively, in premarket trading on Monday, after S&P Dow Jones Indices announced late on Friday that the two companies are set to join the S&P 500 benchmark index.

Replacing Pool Corp and Campbell’s in the S&P 500, Marvell and Flex’s addition will be effective from June 22, per a press release from the provider, which assesses and updates the index on a quarterly basis.

Marvell has been one of the leading candidates for inclusion across the last few quarterly index rebalances. The company has ballooned into a $230 billion chip giant of late, thanks to the wider AI boom, investors chasing momentum, and, yes, Jensen Huang. Flex, which has been part of the S&P MidCap 400 index since 2024, has also grown recently, having played a part in the data center boom with its portfolio spanning across infrastructure and cooling systems.

With today’s premarket movement taken into account, MRVL has now risen almost 40% in the last week alone.

Dickens, Great Expectations, He said, Aha! would you?

Tech tumbles as momentum stocks run into a blowout jobs report and a wave of profit-taking

The AI trade is under some pressure, taking prices back like... a few days. President Donald Trump is not a fan of the price action.

Trump Administration Considers Reclassifying Marijuana As A Less Dangerous Drug

Trulieve to list on NYSE, a first for US cannabis sector

More may be on the way: several other US cannabis companies have announced reverse stock splits with the intention of listing on a major exchange.

Latest Stories

Sherwood Media, LLC and Chartr Limited produce fresh and unique perspectives on topical financial news and are fully owned subsidiaries of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Money, LLC, Robinhood U.K. Ltd, Robinhood Derivatives, LLC, Robinhood Gold, LLC, Robinhood Asset Management, LLC, Robinhood Credit, Inc., Robinhood Ventures DE, LLC and, where applicable, its managed investment vehicles.